JP2014518898A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518898A5
JP2014518898A5 JP2014514452A JP2014514452A JP2014518898A5 JP 2014518898 A5 JP2014518898 A5 JP 2014518898A5 JP 2014514452 A JP2014514452 A JP 2014514452A JP 2014514452 A JP2014514452 A JP 2014514452A JP 2014518898 A5 JP2014518898 A5 JP 2014518898A5
Authority
JP
Japan
Prior art keywords
mcam
antigen
binds
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014514452A
Other languages
English (en)
Japanese (ja)
Other versions
JP6305919B2 (ja
JP2014518898A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/000274 external-priority patent/WO2012170071A1/en
Publication of JP2014518898A publication Critical patent/JP2014518898A/ja
Publication of JP2014518898A5 publication Critical patent/JP2014518898A5/ja
Application granted granted Critical
Publication of JP6305919B2 publication Critical patent/JP6305919B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014514452A 2011-06-06 2012-06-06 Mcamアンタゴニスト及び治療の方法 Expired - Fee Related JP6305919B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161493780P 2011-06-06 2011-06-06
US61/493,780 2011-06-06
US201161527481P 2011-08-25 2011-08-25
US61/527,481 2011-08-25
PCT/US2012/000274 WO2012170071A1 (en) 2011-06-06 2012-06-06 Mcam antagonists and methods of treatment

Publications (3)

Publication Number Publication Date
JP2014518898A JP2014518898A (ja) 2014-08-07
JP2014518898A5 true JP2014518898A5 (OSRAM) 2015-07-30
JP6305919B2 JP6305919B2 (ja) 2018-04-04

Family

ID=46354461

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014514452A Expired - Fee Related JP6305919B2 (ja) 2011-06-06 2012-06-06 Mcamアンタゴニスト及び治療の方法

Country Status (6)

Country Link
US (2) US20140314744A1 (OSRAM)
EP (1) EP2718327A1 (OSRAM)
JP (1) JP6305919B2 (OSRAM)
CA (1) CA2836373A1 (OSRAM)
HK (1) HK1197072A1 (OSRAM)
WO (1) WO2012170071A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2676962C (en) * 2009-06-09 2020-11-10 Centre Hospitalier De L'universite De Montreal Mcam modulation and uses thereof in the management of neuroinflammatory conditions
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗mcam抗體及相關使用方法
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
CA2938931A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
JP2017514458A (ja) 2014-03-12 2017-06-08 プロセナ バイオサイエンシーズ リミテッド Lg4−5に対して特異的な抗−ラミニン4抗体
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
EP3116910A1 (en) 2014-03-13 2017-01-18 Prothena Biosciences Limited Combination treatment for multiple sclerosis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
EP4627096A1 (en) 2022-12-02 2025-10-08 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル,インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
AU2002252444A1 (en) * 2001-03-23 2002-10-08 Board Of Regents, The University Of Texas System Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors
TWI327597B (en) * 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
WO2003057006A2 (en) * 2001-12-28 2003-07-17 Abgenix, Inc. Use of antibodies against the muc18 antigen
JP2005516965A (ja) 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド 抗muc18抗体を使用する方法
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
CN101245101B (zh) * 2008-01-31 2013-10-16 中国科学院生物物理研究所 抗人cd146的单克隆抗体,包含其的组合物,检测可溶性cd146的方法
US8293468B2 (en) * 2009-06-10 2012-10-23 Centre Hospitalier De L'université De Montréal MCAM modulation and uses thereof

Similar Documents

Publication Publication Date Title
JP2014518898A5 (OSRAM)
RU2018132044A (ru) Антитела против тау
WO2015091853A3 (en) Human anti-cd40 human antibodies
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
EP3004168A4 (en) Chimeric antigen receptor-targeting monoclonal antibodies
PH12015501505B1 (en) Antibodies that bind to tl1a and their uses
IL267382A (en) Oncostatin m receptor antigen binding proteins
WO2014189973A3 (en) Anti-transferrin receptor antibodies and methods of use
IL229618B (en) Isolated antibody that binds fcrn
IL221408B (en) Monoclonal antibodies against c-met
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
PT3016681T (pt) Anticorpos humanizados ou quiméricos cd3
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
EP2771031A4 (en) ALPHA SYNNUCLEIN DETECTING HUMANIZED ANTIBODIES
JP2013539454A5 (OSRAM)
JP2014012688A5 (OSRAM)
UA111818C2 (uk) Антитіло проти csf-1r
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
IL236549A0 (en) Antibodies to a beta c-terminal or central epitope and uses thereof
EA201291065A1 (ru) Антитела против vla-4
EP2949750A4 (en) ANTIBODY-BINDING PEPTIDE
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител